Mutant RAS:p-RAF complexes bind MAP2Ks and MAPKs

Stable Identifier
Reaction [binding]
Homo sapiens
Locations in the PathwayBrowser
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
RAF dimerization and phosphorylation downstream of oncogenic RAS and RAF mutations is associated with increased MAP2K and MAPK phosphorylation (Wan et al, 2004; Garnett et al, 2005; reviewed in Holderfield et al, 2014). Although the interactions between oncogenic RAS or RAFs and downstream effectors hasn't been studied in detail, these disease pathways are presumed to recruit MAP2Ks and MAPKs in a scaffold-dependent manner similar to WT (reviewed in Matallanas et al, 2011).
Literature References
PubMed ID Title Journal Year
24957944 Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond

McCormick, F, Deuker, MM, McMahon, M, Holderfield, M

Nat. Rev. Cancer 2014
16364920 Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization

Garnett, MJ, Barford, D, Paterson, H, Rana, S, Marais, R

Mol. Cell 2005
15035987 Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

Niculescu-Duvaz, D, Lee, S, Marais, R, Marshall, CJ, Barford, D, Jones, CM, Good, VM, Springer, CJ, Wan, PT, Garnett, MJ, Roe, SM

Cell 2004
21779496 Raf family kinases: old dogs have learned new tricks

Romano, D, Matallanas, D, Rauch, J, Zebisch, A, Birtwistle, M, Kolch, W, von Kriegsheim, A

Genes Cancer 2011
This event is regulated
Normal reaction
Functional status
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cite Us!